Phaseline

Targets › IGHG1

IGHG1 (Immunoglobulin heavy constant gamma 1): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 3; Other, Genitourinary; next expected readout Feb 2027.

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. (UniProt, P01857)

Open in Phaseline: the race on IGHG1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hansa BiopharmaImlifidase
IgG-degrading enzyme that cleaves IgG into F(ab')2 and Fc fragments, neutralizing Fc-media
IGHG1Phase 3Long Term Efficacy and Safety; Kidney Transplantation in Highly Sensitized PatientsFeb 2027
International Peace Maternity and Child Health Hospitalintravenous immunoglobulin (IVIG)
Intravenous immunoglobulin providing pooled human IgG antibodies for immunomodulation and
IGHG1Phase 2Bronchopulmonary DysplasiaSep 2027

Conditions

Bronchopulmonary Dysplasia (2) Long Term Efficacy and Safety (1) Kidney Transplantation in Highly Sensitized Patients (1)

Modalities

protein or peptide (2)

Companies

Hansa Biopharma (1) International Peace Maternity and Child Health Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.